- Meeting abstract
- Open Access
P01-034 – Cancer in FMF: a population based study Israel
© Brenner et al; licensee BioMed Central Ltd. 2013
- Published: 8 November 2013
- Cervical Cancer
- Cancer Registry
- Familial Mediterranean Fever
Recurrent or persistent inflammation, featuring Familial Mediterranean Fever (FMF), may induce, promote, or influence susceptibility to carcinogenesis. However, the association between FMF and malignancy was rarely described before.
To assess the prevalence of malignancy in FMF.
Demographic data of FMF patients, followed in the national FMF center at Sheba medical center (n=8352) and Hadassah Medical Center (n=1083) were obtained from FMF patient hospital registries. The prevalence of cancer in the general population, and in the study registries was attained from the cancer registry of Israel and analyzed according to age, origin, and cancer type. The Standardized incidence rates (SIR) of the different cancers in FMF patients were calculated and compared to the cancer SIR of the parallel Israeli ethnic population.
Of 9435 FMF patients (4696 men, 4739 female), 363 developed cancer during the years 1970- 2011. FMF female patients developed significantly more lymphoma (Hodgkin and non-Hodgkin) and in-situ cervical cancer than the matched general population, SIR 2.07 (95% CI 1.12-2.99) and 1.86 (95% CI 1.20-2.51), respectively. In contrast, male and female with FMF had a lower gastrointestinal cancer incidence, SIR 0.68 (95% CI 0.42-0.95) and 0.63 (95% CI 0.36-0.90).
The risk for lymphoma and in-situ cervical cancer is increased about twice in FMF. Understanding the underlying mechanism (inflammation? Colchicine? Genetic predisposition?) may improve patient prognosis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.